FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 87055

News■ Mixed

OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors

OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS…
EXHIBIT · mmx.prnewswire.com
KINDNews
DIRECTION■ Mixed
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

THE MACHINE IS STILL READING THIS ITEM — ANALYSIS LANDS WITHIN MINUTES OF INGESTION.

FULL DISPATCH

— New Studies Expand Cesalatamig into Biomarker-driven Precision Immuno-oncology Strategies — Cesalatamig is Also Being Evaluated in Ongoing Phase 2 Studies in the United States and in China ROCKVILLE, Md. , Oct. 19, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical-stage...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

CONTEXTChina

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01prnewswireprnewswire.com · PRIMARY2026-10-19 11:16 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.